Channel Therapeutics Corp. Files 8-K
Ticker: PTHS · Form: 8-K · Filed: 2024-11-21T00:00:00.000Z
Sentiment: neutral
Topics: corporate-update, address-change
TL;DR
Channel Therapeutics Corp. updated its corporate info on 11/21/24. New address in Freehold, NJ.
AI Summary
On November 21, 2024, Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) filed an 8-K report. The filing indicates the company's principal executive office is located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728. The company was incorporated in Nevada and its fiscal year ends on December 31st.
Why It Matters
This filing provides updated corporate information and addresses for Channel Therapeutics Corp., which is important for investors and stakeholders to have the most current contact and location details.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain information about significant financial events, mergers, or regulatory actions.
Key Players & Entities
- Channel Therapeutics Corp. (company) — Registrant
- Chromocell Therapeutics Corp (company) — Former company name
- November 21, 2024 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- 4400 Route 9 South , Suite 1000 Freehold , NJ 07728 (address) — Registrant's principal executive office
FAQ
What is the current name of the registrant?
The current name of the registrant is Channel Therapeutics Corporation.
What was the former name of the company?
The former company name was Chromocell Therapeutics Corp.
When was the name change effective?
The date of the name change was March 23, 2022.
Where is the registrant's principal executive office located?
The registrant's principal executive office is located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728.
In which state was the company incorporated?
The company was incorporated in Nevada.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-11-21 09:00:46
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CHRO The NYSE American LL
Filing Documents
- g084575_8k.htm (8-K) — 24KB
- g084575_ex99-1.htm (EX-99.1) — 11KB
- 0001753926-24-001983.txt ( ) — 211KB
- chro-20241121.xsd (EX-101.SCH) — 3KB
- chro-20241121_lab.xml (EX-101.LAB) — 33KB
- chro-20241121_pre.xml (EX-101.PRE) — 22KB
- g084575_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 21, 2024, the Company issued a press release announcing the change of the Company's name to "Channel Therapeutics Corporation" and reincorporation in the State of Nevada, as well as providing an update on the Company's therapeutic programs. A copy of the Company's press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in such exhibit shall not be deemed filed for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
01. Financial Statements and
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following documents are filed as exhibits to this Form 8-K: Exhibit No. Description Exhibit 99.1 Press Release of Channel Therapeutics Corporation, dated November 21, 2024 Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 21, 2024 Channel Therapeutics Corporation By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer